ArticleFrontiers in medicine2025
Macular vascular density changes in different stages of chronic primary angle-closure glaucoma.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate differences in macular vascular density (MVD) between individuals with chronic primary angle-closure glaucoma (CPACG) and healthy controls, as well as to evaluate cross-sectional changes in MVD at various stages of CPACG. Method: This is a retrospective study based on the epidemiological survey of eye diseases in the local community, including 47 eyes of CPACG subjects (20 eyes at the early stage and 27 eyes at the middle-to-severe stages). All subjects underwent optical coherence tomography angiography (OCTA) imaging to detect MVD, as well as macular retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thickness. Linear regression analysis was performed to evaluate other ophthalmic indicators related to vascular density loss. Results: Compared to the control group, the MVD in CPACG eyes significantly declined by 11.5% in the superficial capillary plexus ( Conclusion: Our study demonstrated that OCTA was a valuable tool for detecting vascular deterioration in CPACG eyes, with a stronger association between MVD and visual field damage. Further research is warranted to explore the potential of MVD as a biomarker for glaucoma progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.